It’s a problem that has plagued European governments for decades, from the credit-crunch bank bailouts of 2008 to more recent ...

As founder of Coatue Management, Philippe Laffont oversees $26.9 billion invested in more than 80 stocks, and though he buys ...

Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals that distract from plans that would hit Americans -- like drug prices.

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

The FDA has approved Ozempic to reduce kidney failure risk in people with type 2 diabetes and chronic kidney disease. Studies ...

People who have been using Ozempic have been complaining of a bizarre side-effect, which has been nicknamed 'Ozempic butt'.

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in the ...

The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in ...